Abstract | PURPOSE: METHODS: An international non-systematic literature review was performed. It included randomized trials of seven drugs of interest and the summaries of the characteristics of these products. This work did not aim comparison between the drugs. RESULTS: Only maximal reported frequencies are presented in this abstract. With prolonged-release alfuzosin, they were 2.8% vs. 1.3% for erectile dysfunction, compared to placebo and 1% vs. 0% for ejaculatory dysfunction. With doxazosin, the incidence was 5.8% vs. 3.3% for erectile dysfunction, 3.6% vs. 1.9% for reduced libido and 0.4% vs. 1.4% for ejaculatory disorders. The incidence of ejaculatory disorders with tamsulosin, was 11% vs. <1% with the placebo and with silodosin, it was 28.1% vs. 1.1%. With finasteride, at 12 months, the highest frequency was 9% vs. 5% for erectile dysfunction, 4.4% vs. 1.5% for ejaculatory disorders and 6.4% vs. 3.4% for reduced libido. At 24 months, for dutatsteride, frequencies were 7.3% vs. 4.0% for erectile dysfunction, 2.2% vs. 0.8% for ejaculatory disorders and 4.2% vs. 2.1% for reduced libido. For tadalafil, a phosphodiesterase-5 inhibitor, and tolerodine, an anticholinergic drug, no negative effect on ejaculation or libido has been reported. For plant extracts, no sexual adverse effects (AEs) were reported among the most common AEs. CONCLUSION: The medications for LUTS-BPH may alter erection, ejaculation or libido. A greater knowledge of the adverse effects of each of these drugs could guide physicians in the clinical management of men with BPH-LUTS.
|
Authors | A Descazeaud, A de La Taille, F Giuliano, F Desgrandchamps, G Doridot |
Journal | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
(Prog Urol)
Vol. 25
Issue 3
Pg. 115-27
(Mar 2015)
ISSN: 1166-7087 [Print] France |
Vernacular Title | Effets négatifs sur la sexualité des traitements médicamenteux des symptômes du bas appareil urinaire liés a l'hypertrophie bénigne de la prostate. |
PMID | 25605342
(Publication Type: Journal Article, Review, Systematic Review)
|
Copyright | Copyright © 2014 Elsevier Masson SAS. All rights reserved. |
Chemical References |
- Adrenergic alpha-Antagonists
|
Topics |
- Adrenergic alpha-Antagonists
(adverse effects)
- Humans
- Lower Urinary Tract Symptoms
(drug therapy, etiology)
- Male
- Prostatic Hyperplasia
(complications)
- Sexual Dysfunction, Physiological
(chemically induced)
|